BACKGROUND: A 30-second aerosol measles vaccination successfully primes children 12 months of age and older but is poorly immunogenic when given to 9-month-old children. We examined the immune responses when increasing the duration to aerosol exposure in 9-month-olds. METHODS:One hundred and thirteen healthy 9-month-old children from Mexico City were enrolled; 58 receivedaerosol EZ measles vaccine for 2.5 minutes and 55 subcutaneously. Measles-specific neutralizing antibodies and cellular responses were measured before and at 3 and 6 months postimmunization. RESULTS:Adaptive immunity was induced in 97% after aerosol and 98% after subcutaneous administration. Seroconversion rates and GMCs were 95% and 373 mIU/mL (95% confidence interval [CI], 441-843) following aerosol vaccination and 91% and 306 mIU/mL (95% CI, 367-597) after subcutaneous administration at 3 months. The percentage of children with a measles-specific stimulation index ≥3 was 45% and 60% in the aerosol versus 55% and 59% in the subcutaneous group at 3 and 6 months, respectively. CD8 memory cell frequencies were higher in the aerosol group at 3 months compared with the subcutaneous group. Adverse reactions were comparable in both groups. CONCLUSIONS: Increasing exposure time to aerosol measles vaccine elicits immune responses that are comparable to those seen when an equivalent dose is administered by the subcutaneous route in 9-month-old infants.
RCT Entities:
BACKGROUND: A 30-second aerosol measles vaccination successfully primes children 12 months of age and older but is poorly immunogenic when given to 9-month-old children. We examined the immune responses when increasing the duration to aerosol exposure in 9-month-olds. METHODS: One hundred and thirteen healthy 9-month-old children from Mexico City were enrolled; 58 received aerosol EZ measles vaccine for 2.5 minutes and 55 subcutaneously. Measles-specific neutralizing antibodies and cellular responses were measured before and at 3 and 6 months postimmunization. RESULTS: Adaptive immunity was induced in 97% after aerosol and 98% after subcutaneous administration. Seroconversion rates and GMCs were 95% and 373 mIU/mL (95% confidence interval [CI], 441-843) following aerosol vaccination and 91% and 306 mIU/mL (95% CI, 367-597) after subcutaneous administration at 3 months. The percentage of children with a measles-specific stimulation index ≥3 was 45% and 60% in the aerosol versus 55% and 59% in the subcutaneous group at 3 and 6 months, respectively. CD8 memory cell frequencies were higher in the aerosol group at 3 months compared with the subcutaneous group. Adverse reactions were comparable in both groups. CONCLUSIONS: Increasing exposure time to aerosol measles vaccine elicits immune responses that are comparable to those seen when an equivalent dose is administered by the subcutaneous route in 9-month-old infants.
Authors: H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin Journal: J Infect Dis Date: 2001-08-22 Impact factor: 5.226
Authors: Hayley A Gans; Linda L Yasukawa; Amanda Alderson; Mary Rinki; Ross DeHovitz; Judith Beeler; Susette Audet; Yvonne Maldonado; Ann M Arvin Journal: J Infect Dis Date: 2004-05-26 Impact factor: 5.226
Authors: A B Sabin; A Flores Arechiga; J Fernández de Castro; J L Sever; D L Madden; I Shekarchi; P Albrecht Journal: JAMA Date: 1983-05-20 Impact factor: 56.272
Authors: Miguel L García-León; Laura C Bonifaz; Bogart Espinosa-Torres; Brenda Hernández-Pérez; Lino Cardiel-Marmolejo; José I Santos-Preciado; Rosa M Wong-Chew Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland Journal: Expert Rev Vaccines Date: 2013-01 Impact factor: 5.217
Authors: Rik L de Swart; Rory D de Vries; Linda J Rennick; Geert van Amerongen; Stephen McQuaid; R Joyce Verburgh; Selma Yüksel; Alwin de Jong; Ken Lemon; D Tien Nguyen; Martin Ludlow; Albert D M E Osterhaus; W Paul Duprex Journal: NPJ Vaccines Date: 2017-08-01 Impact factor: 7.344